Managing cardiovascular disease risk in patients treated with antipsychotics: A multidisciplinary approach

Journal of Multidisciplinary Healthcare

Volumn 7, Issue , 2014, Pages 489-501

  Shulman, Matisyahu ^a   Miller, Avraham ^b   Misher, Jason ^c   Tentler, Aleksey ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Increased mortality; Myocarditis; Prolonged QT; Schizophrenia; Weight gain

Indexed keywords

AMIODARONE; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; GLUCOSE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPERIDONE; LEVOTHYROXINE; LITHIUM SALT; LURASIDONE; METFORMIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; AGE DISTRIBUTION; AGITATION; ARTICLE; ATTITUDE TO HEALTH; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COGNITIVE THERAPY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ELECTROCONVULSIVE THERAPY; ELECTROLYTE DISTURBANCE; EOSINOPHILIA; EVIDENCE BASED PRACTICE; EXERCISE; FEVER; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEALTH EDUCATION; HEART ARRHYTHMIA; HEART DEATH; HEART DEPOLARIZATION; HEART REPOLARIZATION; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEPATITIS C; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; IN VITRO STUDY; INCIDENCE; INTERMEDIATE RISK PATIENT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LOW RISK PATIENT; LUNG EMBOLISM; MAJOR DEPRESSION; METABOLIC SYNDROME X; MONOTHERAPY; MYOCARDITIS; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SMOKING CESSATION; SUDDEN DEATH; SYSTEMATIC REVIEW; T WAVE; TACHYCARDIA; THORAX PAIN; TORSADE DES POINTES; TREATMENT DURATION; TREATMENT INDICATION; UPPER RESPIRATORY TRACT OBSTRUCTION; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84908364959     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S49817     Document Type: Article

References (97)

1. ahrq.gov [homepage on the Internet]. Medical Expenditure Panel Survey Publication Details. US Deaprtment of Health and Human Services; 2014. Available from: http://meps.ahrq.gov/mepsweb/data_stats/Pub_ProdResults_Details.jsp?pt=Statistical_Brief&opt=2&id=941. Accessed August 6, 2014.
2. Ronsley R, Scott D, Warburton W P, et al. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatry. 2013;58(6): 361–639.
3. Matone M, Localio R, Huang YS, dosReis S, Feudtner C, Rubin D. The Relationship between Mental Health Diagnosis and Treatment with Second-Generation Antipsychotics over Time: A National Study of US Medicaid-Enrolled Children. Health Serv Res. 2012;47(5):1836–1860.
4. Laursen TM, Munk-Olsen T, Vestergaard M. Life Expectancy and Cardiovascular Mortality in Persons with Schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–88.
5. Wildgust HJ, Beary M. Are there Modifable Risk Factors Which will Reduce the Excess Mortality in Schizophrenia? J Psychopharmacol. 2010;24(Suppl 4):37–50.
6. Acharya T, Acharya S, Tringali S, Huang J. Association of Antidepressant and Atypical Antipsychotic Use with Cardiovascular Events and Mortality in a Veteran Population. Pharmacotherapy. 2013;33(10):1053–1061.
7. Saravane D, Feve B, Frances Y, et al. Avec le soutien institutionnel du laboratoire Lilly Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale. 2009;35(4):330–339. French.
8. Arnoldy R, Curtis J, Samaras K. The Effects of Antipsychotic Switching on Diabetes in Chronic Schizophrenia. Diabet Med. 2014;31(3):e16–e19.
9. Bradford DW, Cunningham NT, Slubicki MN, et al. An Evidence Synthesis of Care Models to Improve General Medical Outcomes for Individuals With Serious Mental Illness. J Clin Psychiatry. 2013;74(8): e754–e764.
10. Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM. Causes and management of drug-induced long QT syndrome. Proc (Bayl Univ Med Cent). 2010;23(3):250–255.
11. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353–370.
12. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol. 1996;27(1): 76–83.
13. Ya p YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–1372.
14. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–1022.
15. Hollister LE, Kosek JC. Sudden Death During Treatment With Phenothiazine Derivatives. JAMA. 1965;192:1035–1038.
16. Cancro R, Wilder R. A Mechanism of Sudden Death in Chlorpromazine Therapy. Am J Psychiatry. 1970;127(3):368–371.
17. Moore MT, Book MH. Sudden Death in Phenothiazine Therapy. Psychiatr Q. 1970;44(3):389–402.
18. Denvir MA, Sood A, Dow R, Brady AJ, Rankin AC. Thioridazine, diarrhoea and torsades de pointe. J R Soc Med. 1998;91(3):145–147.
19. Glassman AH, Bigger JT. Antipsychotic Drugs: Prolonged QTc Interval, Torsade De Pointes, and Sudden Death. Am J Psychiatry. 2001;158(11):1774–1782.
20. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A Comparison of the Receptor Binding and HERG Channel Affnities for a Series of Antipsychotic Drugs. Eur J Pharmacol. 2002;450(1):37–41.
21. Thomas SH. Drugs, QT Interval Abnormalities and Ventricular Arrhythmias. Adverse Drug React Toxicol Rev. 1994;13(2):77–102.
22. Ray WA, Chung C P, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. N Engl J Med. 2009;360(3):225–235.
23. omh.ny.gov [homepage on the Internet]. Lieberman JA, Merrill D, Parameswaran S, for the APA Council on Research. APA Guidance on the use of Antipsychotic Drugs and Cardiac Sudden Death. Available from: https://www.omh.ny.gov/omhweb/advisories/adult_antipsychotic_use_attachement.html. Accessed May 13, 2014.
24. Manu P, Kane JM, Correll CU. Sudden Death in Psychiatric Patients. J Clin Psychiatry. 2011;72(7):936–941.
25. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiolog y. 2011;22(5):660–670.
26. Ozeki Y, Fujii K, Kurimoto N, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):401–405.
27. Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. Am J Psychiatry. 2013;170(12):1468–1476.
28. Sumić JC, Barić V, Bilić P, Herceg M, Sisek-Sprem M, Jukić V. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Ann Gen Psychiatry. 2007;6:13.
29. Rabkin S W. Aging Effects on QT Interval: Implications for Safety of antipsychotic drugs. J Geriatr Cardiol. 2014;11(1):20–25.
30. Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol. 2011;21(4):365–368.
31. Johnsen E, Aanesen K, Sriskandarajah S, Kroken RA, Løberg EM, Jørgensen HA. QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics. Schizophr Res Treatment. 2013;2013:375020.
32. Curtis LH, Østbye T, Sendersky V, et al. Prescription of Q T- prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114(2): 135–141.
33. psychiatryonline.org [homepage on the Internet]. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders; 2006. Available from: http://psychiatryonline.org/content.aspx?bookid=28§ionid=1665359. Accessed May 13, 2014.
34. National Institute for Health and Care Excellence. NICE Clinical Guideline 178: Psychosis and Schizophrenia in Adults: Treatment and Management. National Institute for Health and Care Excellence; 2014. Available from: http://www.nice.org.uk/nicemedia/live/14382/66534/66534.pdf. Accessed May 13, 2014.
35. Purhonen M, Koponen H, Tiihonen J, Tanskanen A. Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort. Pharmacoepidemiol Drug Saf. 2012;21(11): 1227–1231.
36. Leucht S, Cipriani A, Spineli L, et al. Comparative effcacy and toler-ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
37. Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193–201.
38. US Food and Drug Administration. “Drugs.” Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm085203.htm. Accessed May 13, 2014.
39. Muzyk AJ, Rayfeld A, Revollo JY, Heinz H, Gagliardi J P. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf. 2012;35(7):547–553.
40. Chung AK, Chua SE. Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25(5): 646–666.
41. Poluzzi E, Raschi E, Koci A, et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf. 2013;36(6):467–479.
42. Kane JM. Lurasidone: a clinical overview. J Clin Psychiatry. 2011; 72 Suppl 1:24–28.
43. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. Am J Psychiatry. 1999; 156(11):1686–1696.
44. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of frst episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295–305.
45. Said MA, Sulaiman AH, Habil MH, et al. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antip-sychotics in Malaysia. Singapore Med J. 2012;53(12):801–807.
46. Krane-Gartiser K, Breum L, Glümrr C, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry. 2011;65(5):345–352.
47. Holt RI. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care. 2004;27(8):2086–2087.
48. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125–147.
49. Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM; UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007;33(6):1397–1403.
50. Morrato EH, Newcomer J W, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009;32(6):1037–1042.
51. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer J W. Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated with Second-Generation Antipsychotic Agents. Am J Psychiatry. 2009;166(3): 345–353.
52. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904–912.
53. Ward A, Quon P, Abouzaid S, Haber N, Ahmed S, Kim E. Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation. P T. 2013;38(2):109–115.
54. Lieberman JA, Stroup TS, McEvoy J P, et al. Effectiveness of antip-sychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
55. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796.
56. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–233.
57. Citrome L, Kalsekar I, Baker RA, Hebden T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin. 2014;30(8):1629–1641.
58. Aripiprazole [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc; 2014. Available from: http://www.otsuka-us.com/Documents/Abilify.PI.pdf. Accessed June 19, 2014.
59. Ziprazidone [package insert]. New York, NY: Pfzer Inc; 2014. Available from: http://labeling.pfzer.com/ShowLabeling.aspx?id=584. Accessed June 19, 2014.
60. Lurasidone [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc; 2013. Available from: http://www.latuda.com/LatudaPrescrib-ingInformation.pdf. Accessed June 19, 2014.
61. Paliperidone [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011. Available from: http://www.invega.com/prescribing-information. Accessed September 26, 2014.
62. Quetiapine [package insert]. Wilmington, DE: AstraZeneca; 2014. Available from: http://www1.astrazeneca-us.com/pi/seroquel.pdf. Accessed June 19, 2014.
63. Risperidone [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2014. Available from: http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdf. Accessed June 19, 2014.
64. Asenapine [package insert]. Whitehouse Station, NJ: Merck & Co; 2013. Available from: http://www.merck.com/product/usa/pi_circulars/s/saphris/saphris_pi.pdf. Accessed June 19, 2014.
65. Iloperidone [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf. Accessed June 19, 2014.
66. Olanzapine [package insert]. Indianapolis, IN: Lilly USA, LLC; 2013. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed June 19, 2014.
67. Clozapine [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed June 19, 2014.
68. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsy-chotic medications. Curr Drug Saf. 2009;4(3):229–237.
69. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126.
70. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–759.
71. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090–2095.
72. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10(7):1175–1200.
73. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112.
74. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35(6):205–219.
75. Daumit GL, Dickerson FB, Wang N Y, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594–1602.
76. Cabassa LJ, Ezell JM, Lewis-Fernández R. Lifestyle interventions for adults with serious mental illness: a systematic literature review. Psychiatr Serv. 2010;61(8):774–782.
77. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. Epub March 17, 2014.
78. Wu RR, Zhao J P, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive frst-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352–358.
79. Wu RR, Zhao J P, Shao P, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–193.
80. Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16(4):410–421.
81. Nwosu BU, Meltzer B, Maranda L, et al. A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics. J Pediatr Endocrinol Metab. 2011;24(9–10):619–626.
82. Andrade C. Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins. Bipolar Disord. 2013;15(8):813–823.
83. De Hert M, Kalnicka D, van Winkel R, et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2006;67(12): 1889–1896.
84. Hanssens L, De Hert M, Kalnicka D, et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol. 2007;22(1):43–49.
85. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2): S1–S45.
86. ®. 56th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2014.
87. Meltzer H., Cola PA, Parsa M. Marked elevations of serum cre-atine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacolog y. 1996;15(4):395–405.
88. Walker JL, Smith GH, Gaston MS, Robinson CM. Spontaneous compartment syndrome in association with simvastatin-induced myositis. Emerg Med J. 2008;25(5):305–306.
89. Patier JL, Ferrere F, Moreno-Cobo MA, Echaniz A. Rabdomiólisis producida por la asociación de sinvastatina y risperidona Rhabdomy-olysis caused by the association of simvastatin and risperidone. Med Clin (Barc). 2007;129(11):439. Spanish.
90. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.
91. Richardson K, Schoen M, French B, et al. Statins and Cognitive Function: A Systematic Review. Ann Intern Med. 2013;159(10):688–697.
92. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf. 2007;30(1):47–57.
93. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193): 1841–1845.
94. [No authors listed]. Quetiapine and cardiac muscle disorders. Prescrire Int. 2013;22(140):184.
95. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458–465.
96. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-induced myocarditis identi-fed by an analysis of 38 cases and 47 controls. J Clin Psychiatry. 2010;71(8):976–981.
97. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012;134(2–3):180–186.